A comparison of the efficacy of PYRIDOSTIGMINE (cas 155-97-5) alone and the combination of PYRIDOSTIGMINE (cas 155-97-5) with anticholinergic drugs as pharmacological pretreatment of tabun-poisoned rats and mice

Add time:09/28/2019    Source:infona.pl

The ability of two types of pharmacological pretreatment (PYRIDOSTIGMINE (cas 155-97-5) alone or pyridostigmine in combination with two anticholinergic drugs) to increase the resistance of rats and mice against tabun and to increase the therapeutic efficacy of common antidotal treatment of tabun-poisoned rats and mice was compared. A significant decrease in the LD 5 0 values of tabun was observed when mice as well as rats were pretreated with the prophylactic antidotal mixture consisting of pyridostigmine, benactyzine and trihexyphenidyle, designated PANPAL. Pyridostigmine-pretreated rats were also more resistant against acute lethal effects of tabun but pyridostigmine-induced resistance of rats was not so high as PANPAL-induced resistance. In addition, the pharmacological pretreatment with pyridostigmine alone was not able to protect mice against tabun-induced acute toxicity. The pharmacological pretreatment with pyridostigmine alone was able to increase the efficacy of currently used antidotal treatment (obidoxime in combination with atropine and diazepam) of tabun-induced poisoning, but PANPAL-induced increase in the efficacy of the same antidotal treatment was significantly higher than an increase induced by pyridostigmine alone. PANPAL-induced increase in the efficacy of antidotal treatment of tabun poisoning was also observed in mice. These findings confirm that PANPAL pretreatment of tabun-poisoned rats and mice seems to be much more suitable than currently used pyridostigmine alone.

We also recommend Trading Suppliers and Manufacturers of PYRIDOSTIGMINE (cas 155-97-5). Pls Click Website Link as below: cas 155-97-5 suppliers

Prev:Protective role of RHAPONTIN (cas 155-58-8) in experimental pulmonary fibrosis in vitro and in vivo
Next:Effets neuromusculaires de la PYRIDOSTIGMINE (cas 155-97-5) sur des cultures organotypiques de moelle epiniere et de muscle)